Valuation and Earnings
This table compares Evofem Biosciences and Vaccinex”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evofem Biosciences | $11.39 million | 0.11 | $52.98 million | ($0.06) | -0.17 |
| Vaccinex | $388,000.00 | 7.33 | -$20.25 million | ($48.27) | -0.02 |
Evofem Biosciences has higher revenue and earnings than Vaccinex. Evofem Biosciences is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Insider and Institutional Ownership
0.2% of Evofem Biosciences shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 0.0% of Evofem Biosciences shares are held by company insiders. Comparatively, 51.5% of Vaccinex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Evofem Biosciences and Vaccinex’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evofem Biosciences | -46.42% | -91.97% | -61.93% |
| Vaccinex | N/A | N/A | -383.58% |
Summary
Vaccinex beats Evofem Biosciences on 6 of the 11 factors compared between the two stocks.
About Evofem Biosciences
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
About Vaccinex
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
